Skip to main content
OpenTrials
Completed

NCT Number: NCT02336919

The Use of Texting Messaging to Improve the Hospital-to-community Transition Period in Cardiovascular Disease Patients

Participants will be recruited during their hospitalization for either heart attack or unstable angina and will be randomly assigned to either a text message program (Txt2Prevent) or usual care. They will be texted for the first 60-days after discharge. Texts will include topics regarding self-management and discharge protocols such as reminders to make an appointment with their general practitioner or to refill medication prescriptions. After 60 days, the two groups will be compared for hospital readmission rates, quality of life, medication adherence, and self-management.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

St. Paul's Hospital

Vancouver, British Columbia, V6Z 1Y6, Canada

About this study

Cardiovascular disease is one of the leading causes for hospitalization and death in Canada. Being discharged is often a challenging and overwhelming time. Sometimes patients are readmitted to the hospital shortly in the months following their discharge. Some of these readmissions are due to information transfer being poor or insufficient.

Previous studies have looked at whether text messaging can be a simple, cost-effective way to help patients. Therefore, we wish to investigate the effectiveness of using text messaging to help heart patients after they are discharged from the hospital.

The goal of this study is to determine the impact of a pilot text-messaging intervention program (Txt2Prevent) that supports coronary syndrome (heart attack and unstable angina) patients for 60 days after their hospital discharge. The program will include information about follow-up care, medication use, and healthy lifestyle behaviours. The texts will be sent at relevant times during the patients' recovery.

The primary objective is compare self-management between the usual care patients versus the Txt2prevent patients. We hypothesize that the Txt2Prevent group will have better self-management than the usual care group.

The secondary objective is compare medication adherence, and health-related quality of life as well as readmission and mortality rates between the two patient groups. We hypothesize that the Txt2Prevent group will have better outcomes for these variables.

The study population is acute coronary syndrome patients at St. Paul's hospital who are discharged. Participants will be randomly assigned to one of two groups-a usual care group and the usual care plus the Txt2Prevent text messaging program group. All participants will undergo a baseline assessment that includes:

  • Demographics, medical history, medication use and technology use information
  • Self-management skills
  • Health-related quality of life

After 60 days, participants will be contacted again to perform a follow up assessment that includes:

  • Information on readmission, medication use, the use of health services such as cardiac rehab
  • Self-management skills
  • Health-related quality of life
  • Medication adherence

In both the baseline and follow-up assessments, information may be obtained from the patient's medical chart or records (e.g. medical history) or self-report.

After the intervention, some intervention participants will be contacted to complete a semi-structured interview about their experiences with the Txt2Prevent program.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • are an acute coronary syndrome patient on the non-surgical ward who will be discharged home
  • own a phone with text-messaging capabilities and have the ability to access new text messages
  • have the ability to provide informed consent
  • have the ability to read and understand English

Exclusion criteria

  • have a pre-scheduled surgical procedure within the duration of the study
  • if it is expected that they will not survive the duration of the study due to non-cardiovascular reasons
  • are currently enrolled in another research project regarding CVDs that would interfere with the study outcomes.

Treatment and study plan

Txt2Prevent

Behavioral

A 60-day text messaging program called Txt2Prevent (see description in the arm description).

Primary outcomes

  1. Self-management as measured by the Health Education Impact Questionnaire by Osborne et al.

    Time frame: Pre- and post-study period (0 and 60 days)

Secondary outcomes

  1. Medication Adherence as measured by the Morisky Medication Adherence Scale by Morisky et al.

    Time frame: Post-study period (60 days)

  2. Health-related quality of life as measured by the EuroQoL 5D-5L by the EuroQoL group

    Time frame: Pre- and post-study period (0 and 60 days)

  3. Hospital readmissions

    Time frame: Assessed at the end of the study (day 60)

  4. Mortality

    Time frame: Assessed at the end of the study (day 60)

Sponsors and collaborators

Lead sponsor

Simon Fraser University

Other

Collaborators

  • Canadian Institutes of Health Research (CIHR)
  • McMaster University
  • Providence Health & Services
  • University of British Columbia

Registry information

Official study title

The Use of Text Messaging to Improve the Hospital-community Transition and Prevent Readmission in Patients With Cardiovascular Disease (Txt2Prevent)

Acronym: Txt2Prevent

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Jan 13, 2015
Registry last updated
Apr 26, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.